IL23A and inflammatory bowel disease: Anti-TNFα and IL-23 inhibitors currently represent the main cytokine-based therapeutic strategies for patients with coexisting IBD and SpA, except for etanercept, which is not indicated in IBD, and preferring the use of ustekinumab in peripheral but not axial SpA.